STRIVE-02: First-in-Human B7H3 CAR T-Cells for Pediatric Patients With Relapsed/Refractory Solid Tumors
Three of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.
Cilta-Cel Yields 100% ORR in Patients With Early Relapse of Multiple Myeloma
Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.
Early Bone Marrow MRD Status May Determine CAR-T Therapy Response in Myeloma
Regardless of bone marrow cellularity, bone marrow minimal residual disease (MRD) negativity at month 1 correlated with deep response and prolonged PFS.
Exploring New Paths for CAR T-Cell Therapy Research in Multiple Myeloma
Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.
CAR T-Cell Therapy Directed at CLDN18.2 Effective in Gastric, Pancreatic Adenocarcinoma
Findings from the US-based study align with results from a phase 1b/2 study completed in China of CT041 in patients with gastric and gastroesophageal junction adenocarcinoma.
Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid Tumors
The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.
POLARIS: OriCAR-017 Elicits 100% ORR in Patients With Relapsed/Refractory Multiple Myeloma
The phase 1, open-label, single-arm study demonstrated favorable safety and robust efficacy for the autologous GPRC5D-directed CAR-T cell therapy.
BCMA/CD19 Dual-Targeting CAR-T GC012F Continues to Display Durable Response for RRMM in Updated Results
Data were presented at ASCO 2021 and EHA 2021 for the initial 19 patients. Now, investigators are painting a fuller picture with an additional 9.
Novel Healthy Cell Sparing CAR T-cell Therapy Enters Clinical Studies for Solid Tumors
The BASECAMP-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel CAR T-cell therapy with a target antigen activator and a HLA LOH-based blocker.
TCR Therapy Shows Anti-Tumor Activity in MRCLS
Higher-dose lymphodepleting regimens led to higher toxicity but high response rates.
Cilta-Cel Shows Promise in Earlier Lines of Treatment in Patients With Progressive Multiple Myeloma
Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.
Lete-Cel Exhibits Anti-Tumor Activity, Long Median PFS in Patients With Myxoid/Round Cell Liposarcoma
“Therapy was found to be safe and tolerable. This initial data formed the basis for further exploration that is currently ongoing in the IGNYTE-ESO study,” investigator Sandra P. D’Angelo, MD, tells CGTL.
Binod Dhakal, MD, on Developing Controllable CAR T-Cell Therapies for Multiple Myeloma
The associate professor of medicine at Medical College of Wisconsin discussed advantages of the ARC-SparX platform.
Brexu-Cel Shows Efficacy in Mantle Cell Lymphoma in Real-World Setting
High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.
Axi-Cel Shows Favorable Outcomes in Large B-Cell Lymphoma Regardless of Race, Ethnicity
No differences were found in overall survival and progression free survival across races.
CGTLive’s Weekly Rewind – June 3, 2022
Review top news and interview highlights from the week ending June 3, 2022.
Allogeneic CAR T-Cell Therapy Well-Tolerated and Effective Across B-Cell Malignancies
A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.
CAR T-Cell Therapy Yields High Response Rates in B-NHL
Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.
ICER Finds Beti-Cel Superior to Standard-of-Care for β-Thalassemia
Beti-cel was rated a B+ for lingering questions about durability and unknown risks.
NK Cell Therapy Avelumab Combo Well Tolerated With Some Clinical Activity in Sarcoma
A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.
Tim Miller, PhD, on Supporting Gene Therapy Development
The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
Around the Helix: Cell and Gene Therapy Company Updates – June 1, 2022
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Val-Rox BLA for Hemophilia A Delayed Again
BioMarin now expects to file in September 2022 instead of June.
Donald Kohn, MD, on the Trajectory of Gene Therapy
The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
Liso-Cel Yields High Response Rates and Positive PROs in LBCL
Treated patients had significant improvements in fatigue and lymphoma symptoms.
Lifileucel Shows Promising Data in Advanced Melanoma
A lower objective response rate in cohort 4 reflected a higher disease burden with a greater number of tumors.
FDA Approves Tisa-Cel Expanded Indication in R/R Follicular Lymphoma
The approval was based on data from the phase 2 ELARA clinical trial, in which a complete response of more than 65% was observed.
Expediting the Development of Patient-Specific iSPC Cell Therapies
Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.
Lentiviral Cell Therapy Normalizes Hemoglobin in Pyruvate Kinase Deficiency
RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.
Noopur Raje, MD, on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma
The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.
